Clover Biopharmaceuticals Ltd. (HK:2197)
:2197
Want to see HK:2197 full AI Analyst Report?
Total Valuation
Clover Biopharmaceuticals Ltd. has a market cap or net worth of HK$3.86B. The enterprise value is HK$3.10B.
Market CapHK$3.86B
Enterprise ValueHK$3.10B
Share Statistics
Clover Biopharmaceuticals Ltd. has 1,298,038,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,298,038,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Clover Biopharmaceuticals Ltd.’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 19.32%.
Return on Equity (ROE)0.11
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)19.32%
Return on Capital Employed (ROCE)0.19
Revenue Per Employee11.38K
Profits Per Employee-665.95K
Employee Count300
Asset Turnover<0.01
Inventory Turnover2.76
Valuation Ratios
The current PE Ratio of Clover Biopharmaceuticals Ltd. is ―. Clover Biopharmaceuticals Ltd.’s PEG ratio is 0.17.
PE Ratio―
PS Ratio775.86
PB Ratio-1.47
Price to Fair Value-1.47
Price to FCF-13.90
Price to Operating Cash Flow-16.70
PEG Ratio0.17
Income Statement
In the last 12 months, Clover Biopharmaceuticals Ltd. had revenue of 3.41M and earned -199.78M in profits. Earnings per share was -0.16.
Revenue3.41M
Gross Profit-23.85M
Operating Income-247.75M
Pretax Income-199.78M
Net Income-199.78M
EBITDA-221.24M
Earnings Per Share (EPS)-0.16
Cash Flow
In the last 12 months, operating cash flow was -195.67M and capital expenditures -33.61K, giving a free cash flow of -195.71M billion.
Operating Cash Flow-195.67M
Free Cash Flow-195.71M
Free Cash Flow per Share-0.15
Dividends & Yields
Clover Biopharmaceuticals Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.58
52-Week Price Change1314.29%
50-Day Moving Average2.36
200-Day Moving Average1.93
Relative Strength Index (RSI)63.56
Average Volume (3m)29.82M
Important Dates
Clover Biopharmaceuticals Ltd. upcoming earnings date is Aug 26, 2026, Before Open (Not Confirmed).
Last Earnings DateMar 25, 2026
Next Earnings DateAug 26, 2026
Ex-Dividend Date―
Financial Position
Clover Biopharmaceuticals Ltd. as a current ratio of 0.19, with Debt / Equity ratio of -0.59%
Current Ratio0.19
Quick Ratio0.19
Debt to Market Cap<0.01
Net Debt to EBITDA1.18
Interest Coverage Ratio-674.64
Taxes
In the past 12 months, Clover Biopharmaceuticals Ltd. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Clover Biopharmaceuticals Ltd. EV to EBITDA ratio is -10.79, with an EV/FCF ratio of -12.53.
EV to Sales699.45
EV to EBITDA-10.79
EV to Free Cash Flow-12.53
EV to Operating Cash Flow-12.53
Balance Sheet
Clover Biopharmaceuticals Ltd. has HK$286.15M in cash and marketable securities with HK$10.62M in debt, giving a net cash position of HK$275.53M billion.
Cash & Marketable SecuritiesHK$286.15M
Total DebtHK$10.62M
Net CashHK$275.53M
Net Cash Per ShareHK$0.21
Tangible Book Value Per Share-HK$1.45
Margins
Gross margin is -681.22%, with operating margin of -7256.41%, and net profit margin of -5851.41%.
Gross Margin-681.22%
Operating Margin-7256.41%
Pretax Margin-5851.41%
Net Profit Margin-5851.41%
EBITDA Margin-6479.74%
EBIT Margin-7256.41%
Analyst Forecast
The average price target for Clover Biopharmaceuticals Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-90.96%
EPS Growth Forecast77.66%